| Deanna J Schmidt, CNM | |
|
1032 S Cesar E Chavez Dr, Milwaukee, WI 53204-2203 | |
| (414) 672-1353 | |
| (414) 672-0191 |
| Full Name | Deanna J Schmidt |
|---|---|
| Gender | Female |
| Speciality | Advanced Practice Midwife |
| Location | 1032 S Cesar E Chavez Dr, Milwaukee, Wisconsin |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619168226 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | 148814 (Wisconsin) | Primary |
| Entity Name | Columbia St Marys Hospital Milwaukee Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023064482 PECOS PAC ID: 5890604722 Enrollment ID: O20031105000057 |
News Archive
Researchers have found that the budding yeast (Saccharomyces cerevisiae) is an acceptable model system to study KP1019, an anti-cancer drug that uses ruthenium, a rare metal, a new study found. Researchers had previously been interested in studying KP1019 because it is believed to cause cancer cell death and is not known to have negative secondary side effects for healthy tissues.
Belly fat, known clinically as central obesity, has been linked to the development of asthma in a new study.
A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. Bevacizumab is used to treat patients with certain cancers whose cancer has spread. The study appears in the journal Cancer.
LivaNova PLC , a market-leading medical technology company, today announced its latest VNS Therapy Systems ("VNS Therapy") received CE Mark for expanded MRI labeling. VNS Therapy is now the only implantable device indicated for epilepsy therapy that allows patients to have high-quality 1.5T and 3T MRI scans without the need for special equipment.
› Verified 7 days ago
| Entity Name | Aurora Medical Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427271378 PECOS PAC ID: 6709794258 Enrollment ID: O20031105000725 |
News Archive
Researchers have found that the budding yeast (Saccharomyces cerevisiae) is an acceptable model system to study KP1019, an anti-cancer drug that uses ruthenium, a rare metal, a new study found. Researchers had previously been interested in studying KP1019 because it is believed to cause cancer cell death and is not known to have negative secondary side effects for healthy tissues.
Belly fat, known clinically as central obesity, has been linked to the development of asthma in a new study.
A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. Bevacizumab is used to treat patients with certain cancers whose cancer has spread. The study appears in the journal Cancer.
LivaNova PLC , a market-leading medical technology company, today announced its latest VNS Therapy Systems ("VNS Therapy") received CE Mark for expanded MRI labeling. VNS Therapy is now the only implantable device indicated for epilepsy therapy that allows patients to have high-quality 1.5T and 3T MRI scans without the need for special equipment.
› Verified 7 days ago
| Entity Name | Sixteenth Street Community Health Centers Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417912999 PECOS PAC ID: 6709876857 Enrollment ID: O20040512001352 |
News Archive
Researchers have found that the budding yeast (Saccharomyces cerevisiae) is an acceptable model system to study KP1019, an anti-cancer drug that uses ruthenium, a rare metal, a new study found. Researchers had previously been interested in studying KP1019 because it is believed to cause cancer cell death and is not known to have negative secondary side effects for healthy tissues.
Belly fat, known clinically as central obesity, has been linked to the development of asthma in a new study.
A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. Bevacizumab is used to treat patients with certain cancers whose cancer has spread. The study appears in the journal Cancer.
LivaNova PLC , a market-leading medical technology company, today announced its latest VNS Therapy Systems ("VNS Therapy") received CE Mark for expanded MRI labeling. VNS Therapy is now the only implantable device indicated for epilepsy therapy that allows patients to have high-quality 1.5T and 3T MRI scans without the need for special equipment.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Deanna J Schmidt, CNM Po Box 778789, Chicago, IL 60677-8789 Ph: (414) 672-1353 | Deanna J Schmidt, CNM 1032 S Cesar E Chavez Dr, Milwaukee, WI 53204-2203 Ph: (414) 672-1353 |
News Archive
Researchers have found that the budding yeast (Saccharomyces cerevisiae) is an acceptable model system to study KP1019, an anti-cancer drug that uses ruthenium, a rare metal, a new study found. Researchers had previously been interested in studying KP1019 because it is believed to cause cancer cell death and is not known to have negative secondary side effects for healthy tissues.
Belly fat, known clinically as central obesity, has been linked to the development of asthma in a new study.
A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. Bevacizumab is used to treat patients with certain cancers whose cancer has spread. The study appears in the journal Cancer.
LivaNova PLC , a market-leading medical technology company, today announced its latest VNS Therapy Systems ("VNS Therapy") received CE Mark for expanded MRI labeling. VNS Therapy is now the only implantable device indicated for epilepsy therapy that allows patients to have high-quality 1.5T and 3T MRI scans without the need for special equipment.
› Verified 7 days ago
Tracy Blair Wandtke Herrmann, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 1032 S Cesar E Chavez Dr, Milwaukee, WI 53204 Phone: 414-672-1353 Fax: 414-672-4265 | |
Jenna Ruth Haeberle, APRN, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 1032 S Cesar E Chavez Dr, Milwaukee, WI 53204 Phone: 414-672-1353 | |
Camilla Lynn Roe, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 1502 S Layton Blvd, Milwaukee, WI 53215 Phone: 414-643-6454 | |
Kathleen Storck, CNM, APNP Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 3727 W Wisconsin Ave, Milwaukee, WI 53208 Phone: 414-291-2626 | |
Anne Katherine Lewandoski, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 945 N 12th St, Women's Health Center, Milwaukee, WI 53233 Phone: 414-219-5797 | |
Susan Joyce Totzke, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 1218 W Kilbourn Ave, Suite 200, Milwaukee, WI 53233 Phone: 414-287-1000 Fax: 414-287-1014 | |
Megan Vosswinkel, CNM, APNP Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 2555 N Dr Martin Luther King Dr, Milwaukee, WI 53212 Phone: 414-372-8080 Fax: 414-562-8447 |